Edwards Lifesciences Corporation
Can Edwards keep TAVR growing through a reopened Medicare coverage decision and earlier treatment, while new mitral and tricuspid valves scale fast enough to offset harder comparisons?
Last 4 earnings calls · through Q2 FY2026
Bull case
TAVR demand expanding
The bull case is that TAVR demand is expanding as treatment moves earlier, so guidance has risen at every call as evidence reaches more patients.
Medicare coverage and referral
A reopened Medicare coverage review and faster referral of aortic stenosis patients could widen the treated population well beyond current forecasts.
Cash funds investment and buybacks
Cash generation exceeds what the business needs, so factory capacity, small acquisitions and buybacks are funded internally, which lifts earnings per share over time.
Bear case
Single-procedure dependence
The bear case is that most revenue still comes from one procedure, so hospital capacity, reimbursement policy and a single competitor set the growth rate.
Competitor exit benefit ends
Recent growth also leaned on a competitor leaving Europe, a one-time benefit that has now run out just as year-over-year comparisons become harder in the second half.
Pipeline options unproven
The failed acquisition and a moderate-disease trial that has not read out leave the next leg of growth uncertain and largely outside current guidance.
Margins rely on cost control
Operating margin gains lean on spending timing and cost discipline while gross margin has not improved, so further expansion depends on revenue scale.
Bull and bear points
Growth & Execution
In short: TAVR guidance keeps rising and new mitral and tricuspid products are scaling, but comparisons get harder.
TAVR growth guidance has been raised at every call
Management now expects faster TAVR growth than it did a year ago, which supports the claim that earlier treatment and the asymptomatic label are widening the market rather than only shifting share.
Tone shiftQ2 FY2025 → Q2 FY2026Three transcatheter products are scaling at once
TMTT revenue reached $199 million in the quarter, 11% of segment revenue, and management raised its 2026 sales range for the group, giving Edwards several independent ways to grow in mitral and tricuspid disease.
Q2 FY2026 callAsymptomatic approval is lifting diagnosis and referral
Physicians are ordering more echocardiograms and referring patients sooner, which adds new patients to the treatment pool instead of only moving existing ones through the system faster.
Q4 FY2025 call
Competitor exit stops helping growth from the third quarter
Edwards describes the second quarter of 2026 as the last with benefit from a rival leaving Europe, so TAVR growth from here must come from procedure expansion and share gains against the competitors that remain.
Q2 FY2026 callFailed acquisition leaves no aortic regurgitation entry
Edwards pursued JenaValve specifically to reach aortic regurgitation patients; with the deal closed out and related charges booked, that growth option must be rebuilt internally or bought again.
Tone shiftQ2 FY2025 → Q4 FY2025Moderate aortic stenosis results are still unknown
The PROGRESS trial tests TAVR in a patient group management says is at least as large as severe disease, but the data are not out, so a further TAVR indication is not yet in the forecast.
Q4 FY2025 call
Profitability & Financial Strength
In short: Operating margin and free cash flow are strong, while gross margin has stalled and the tax rate is rising.
Operating margin is expanding faster than the long-term plan
Operating margin was 29.5% in the second quarter of 2026, up 2.6 points, and management targets 50 to 100 basis points a year; the 2026 step-up is flattered by dropping planned JenaValve spending.
Q4 FY2025 callFree cash flow covers investment and buybacks
Free cash flow of $1.4 billion over the last twelve months equals 22% of revenue, funding factory capacity for new valves and about $1.5 billion of remaining buyback authorization without borrowing.
Q2 FY2026 call
Gross margin has stalled and is guided to the low end
Gross margin was 77.5% in the second quarter of 2026, and management expects the full year at the bottom of its range because of currency hedging and the cost of manufacturing newly launched therapies.
Q2 FY2026 callTax rate rises to the top of the guided range
Pillar Two rules and a California limit on research credits push the effective tax rate to the high end of the guided range, absorbing part of the operating gain before it reaches earnings per share.
Q2 FY2026 call
Market Position
In short: SAPIEN leads TAVR with the deepest durability data, but growth depends on reimbursement and procedure volumes.
Medicare coverage review moved from request to draft
A year ago management was asking CMS to reopen the national coverage decision; a draft now exists with a pathway for asymptomatic coverage and a final policy expected in September, which could ease access from 2027.
Tone shiftQ2 FY2025 → Q2 FY2026SAPIEN has the longest durability record in TAVR
Seven-year PARTNER 3 and ten-year PARTNER 2 data let Edwards argue that valve durability and lifetime management favor its platform, which is the basis for defending price against lower-priced rivals.
Q2 FY2026 call
Japanese market share was lost to new entrants
Edwards is still working to win back ground in Japan after competitors entered, showing that leadership in an individual country can erode even while the global franchise grows.
Q2 FY2025 callTAVR supplies most of the segment revenue
TAVR is 72% of segment revenue, so company results depend on one procedure, one Medicare coverage policy and one competitive position in aortic stenosis.
Filed financials